Novavax Inc NVAX

Healthcare Biotechnology

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

NDAQ:NVAX - Post by User

Novavax Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson May 10, 2024 10:00am

63 Views

Post# 36033342

Novavax shares jump 40% on $1.2 billion licensing deal with

Breaking News: $NVAX Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses2024-05-10 05:53:45 ET Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company’s fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal with French pharmaceutical giant Sanofi SA. Despite rep...NVAX - Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta